首页 > 最新文献

Pediatric Diabetes最新文献

英文 中文
ISPAD Clinical Practice Consensus Guidelines 2022: Psychological care of children, adolescents and young adults with diabetes. ISPAD临床实践共识指南2022:儿童、青少年和青年糖尿病患者的心理护理。
IF 3.4 3区 医学 Q1 Medicine Pub Date : 2022-12-01 DOI: 10.1111/pedi.13428
Maartje de Wit, Katarzyna A Gajewska, Eveline R Goethals, Vincent McDarby, Xiaolei Zhao, Given Hapunda, Alan M Delamater, Linda A DiMeglio
several
{"title":"ISPAD Clinical Practice Consensus Guidelines 2022: Psychological care of children, adolescents and young adults with diabetes.","authors":"Maartje de Wit, Katarzyna A Gajewska, Eveline R Goethals, Vincent McDarby, Xiaolei Zhao, Given Hapunda, Alan M Delamater, Linda A DiMeglio","doi":"10.1111/pedi.13428","DOIUrl":"https://doi.org/10.1111/pedi.13428","url":null,"abstract":"several","PeriodicalId":19797,"journal":{"name":"Pediatric Diabetes","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/78/66/PEDI-23-1373.PMC10107478.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9833279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 15
Type 1 diabetes knowledge assessment: The KAT-1 validation study. 1型糖尿病知识评估:KAT-1验证研究。
IF 3.4 3区 医学 Q1 Medicine Pub Date : 2022-12-01 DOI: 10.1111/pedi.13414
Anastasia Albanese-O'Neill, Jann MacInnes, Michael J Haller, Janey Adams, Nicole Thomas, Angelina Bernier

Objective: This study sought to examine the reliability and validity of a novel pediatric type 1 diabetes knowledge assessment (KAT-1) designed for children, adolescents, young adults and their parents/guardians. The instrument was designed to be integrated into the clinic workflow to obtain objective data electronically.

Research design and methods: KAT-1 was developed by a multidisciplinary team and includes 11 independent topical subscales. Forty children/caregivers participated in a pilot study; their feedback was used to improve item clarity and readability. Subsequently, a validation study was performed in 200 participants (100 children/adolescents/young adults with type 1 diabetes ages 11-21 years and 100 parents/guardians of children with type 1 diabetes ages 1-15 years) to examine correlations between the KAT-1 scores and Revised Diabetes Knowledge Test (DKT2) scores and HbA1c. An item analysis was conducted to determine internal consistency and reliability; topical subscales were evaluated using Cronbach's alpha.

Results: Total KAT-1 scores were positively correlated with DKT2 scores r = 0.674, p < 0.001, and negatively correlated with HbA1c, r = -0.3, p < 0.001. All KAT-1 subscales were positively and significantly correlated with one another and with total KAT-1 score. Internal consistency of total KAT-1 score was strong (Cronbach's α = 0.938, mean score 84.6, SD = 16.1) and 9 of 11 independent topical subscales demonstrated strong internal consistency. Completion time for subscales was <5 min.

Conclusions: KAT-1 is a valid instrument to assess type 1 diabetes knowledge. The instrument's short topical subscales can be used to objectively assess specific knowledge and individualize diabetes education. KAT-1 has been integrated into our electronic health record (EPIC) and is available online at no cost.

目的:本研究旨在检验为儿童、青少年、年轻人及其父母/监护人设计的新型儿科1型糖尿病知识评估(KAT-1)的信度和效度。该仪器被设计为集成到临床工作流程中,以电子方式获取客观数据。研究设计和方法:KAT-1由一个多学科团队开发,包括11个独立的主题子量表。40名儿童/照料者参加了一项试点研究;他们的反馈被用来提高项目的清晰度和可读性。随后,在200名参与者中进行了一项验证研究(100名11-21岁的1型糖尿病儿童/青少年/年轻人和100名1-15岁1型糖尿病儿童的父母/监护人),以检查KAT-1分数和修订糖尿病知识测试(DKT2)分数和HbA1c之间的相关性。进行项目分析以确定内部一致性和信度;局部分量表采用Cronbach's alpha进行评估。结果:KAT-1总分与DKT2总分呈正相关(r = 0.674, p)。结论:KAT-1总分是评估1型糖尿病知识的有效工具。该工具的短主题分量表可用于客观评估特定知识和个性化糖尿病教育。KAT-1已集成到我们的电子健康记录(EPIC)中,并可免费在线获取。
{"title":"Type 1 diabetes knowledge assessment: The KAT-1 validation study.","authors":"Anastasia Albanese-O'Neill,&nbsp;Jann MacInnes,&nbsp;Michael J Haller,&nbsp;Janey Adams,&nbsp;Nicole Thomas,&nbsp;Angelina Bernier","doi":"10.1111/pedi.13414","DOIUrl":"https://doi.org/10.1111/pedi.13414","url":null,"abstract":"<p><strong>Objective: </strong>This study sought to examine the reliability and validity of a novel pediatric type 1 diabetes knowledge assessment (KAT-1) designed for children, adolescents, young adults and their parents/guardians. The instrument was designed to be integrated into the clinic workflow to obtain objective data electronically.</p><p><strong>Research design and methods: </strong>KAT-1 was developed by a multidisciplinary team and includes 11 independent topical subscales. Forty children/caregivers participated in a pilot study; their feedback was used to improve item clarity and readability. Subsequently, a validation study was performed in 200 participants (100 children/adolescents/young adults with type 1 diabetes ages 11-21 years and 100 parents/guardians of children with type 1 diabetes ages 1-15 years) to examine correlations between the KAT-1 scores and Revised Diabetes Knowledge Test (DKT2) scores and HbA1c. An item analysis was conducted to determine internal consistency and reliability; topical subscales were evaluated using Cronbach's alpha.</p><p><strong>Results: </strong>Total KAT-1 scores were positively correlated with DKT2 scores r = 0.674, p < 0.001, and negatively correlated with HbA1c, r = -0.3, p < 0.001. All KAT-1 subscales were positively and significantly correlated with one another and with total KAT-1 score. Internal consistency of total KAT-1 score was strong (Cronbach's α = 0.938, mean score 84.6, SD = 16.1) and 9 of 11 independent topical subscales demonstrated strong internal consistency. Completion time for subscales was <5 min.</p><p><strong>Conclusions: </strong>KAT-1 is a valid instrument to assess type 1 diabetes knowledge. The instrument's short topical subscales can be used to objectively assess specific knowledge and individualize diabetes education. KAT-1 has been integrated into our electronic health record (EPIC) and is available online at no cost.</p>","PeriodicalId":19797,"journal":{"name":"Pediatric Diabetes","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10440504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
ISPAD Clinical Practice Consensus Guidelines 2022: Diabetes technologies: Insulin delivery. ISPAD临床实践共识指南2022:糖尿病技术:胰岛素输送。
IF 3.4 3区 医学 Q1 Medicine Pub Date : 2022-12-01 DOI: 10.1111/pedi.13421
Jennifer L Sherr, Melissa Schoelwer, Tiago Jeronimo Dos Santos, Leenatha Reddy, Torben Biester, Alfonso Galderisi, Jacobus Cornelius van Dyk, Marisa E Hilliard, Cari Berget, Linda A DiMeglio
LGS is strongly recommended for all people with T1D to reduce the severity and duration of hypoglycemia. A
{"title":"ISPAD Clinical Practice Consensus Guidelines 2022: Diabetes technologies: Insulin delivery.","authors":"Jennifer L Sherr,&nbsp;Melissa Schoelwer,&nbsp;Tiago Jeronimo Dos Santos,&nbsp;Leenatha Reddy,&nbsp;Torben Biester,&nbsp;Alfonso Galderisi,&nbsp;Jacobus Cornelius van Dyk,&nbsp;Marisa E Hilliard,&nbsp;Cari Berget,&nbsp;Linda A DiMeglio","doi":"10.1111/pedi.13421","DOIUrl":"https://doi.org/10.1111/pedi.13421","url":null,"abstract":"LGS is strongly recommended for all people with T1D to reduce the severity and duration of hypoglycemia. A","PeriodicalId":19797,"journal":{"name":"Pediatric Diabetes","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10441131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 25
Issue Information 问题信息
IF 3.4 3区 医学 Q1 Medicine Pub Date : 2022-12-01 DOI: 10.1111/pedi.13228
{"title":"Issue Information","authors":"","doi":"10.1111/pedi.13228","DOIUrl":"https://doi.org/10.1111/pedi.13228","url":null,"abstract":"","PeriodicalId":19797,"journal":{"name":"Pediatric Diabetes","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46905625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Utility of plasma beta-hydroxybutyrate to define resolution of diabetic ketoacidosis. 血浆β -羟基丁酸测定糖尿病酮症酸中毒的疗效。
IF 3.4 3区 医学 Q1 Medicine Pub Date : 2022-12-01 Epub Date: 2022-10-29 DOI: 10.1111/pedi.13437
Elise Schlissel Tremblay, Kate Millington, Yunhong Wu, David Wypij, Yufan Yang, Michael S D Agus, Joseph Wolfsdorf

Background: Diabetic ketoacidosis (DKA) is a common, life-threatening complication of type 1 diabetes (T1D) characterized by unregulated ketogenesis caused by relative or absolute insulin deficiency. DKA management requires frequent biochemical monitoring. Plasma ß-hydroxybutyrate (BOHB) has not been included in traditional definitions of DKA resolution.

Objective: The aim of this study was to determine a cut-point level of BOHB to define DKA resolution in patients with T1D treated with intravenous (IV) insulin.

Subjects: We identified patients with T1D receiving IV insulin for DKA treatment at a quaternary children's hospital from January 1, 2017 through December 31, 2020 who had plasma measurements of BOHB after DKA onset and whose DKA resolved by traditional laboratory criteria (venous pH (vpH) ≥ 7.3, serum bicarbonate (HCO3 ) ≥ 15 mmol/L, and/or anion gap (AG) ≤ 14 mmol/L).

Methods: Associations between plasma BOHB and vpH, HCO3 , and AG were evaluated via scatterplots. Receiver operating characteristic (ROC) curves and area under the curve (AUC) were used to evaluate BOHB cut-points to predict DKA resolution.

Results: We analyzed 403 patients with 471 unique encounters. Plasma BOHB showed the most robust relationship with AG. The ROC curve comparing plasma BOHB to the accepted definition of DKA resolution, AG ≤14 mmol/L, had an AUC of 0.92. A BOHB value of <1.5 mmol/L had a sensitivity of 83% and specificity of 87%; this cut-point correctly classified 86% of the observations.

Conclusions: A plasma BOHB value of <1.5 mmol/L can be used to define resolution of DKA.

背景:糖尿病酮症酸中毒(DKA)是一种常见的危及生命的1型糖尿病(T1D)并发症,其特征是由相对或绝对胰岛素缺乏引起的酮生成不调节。DKA管理需要经常进行生化监测。血浆ß-羟基丁酸(BOHB)未包括在DKA分辨率的传统定义中。目的:本研究的目的是确定BOHB的切点水平,以确定静脉注射(IV)胰岛素治疗的T1D患者的DKA消退。研究对象:我们确定了2017年1月1日至2020年12月31日在一家第四儿童医院接受静脉胰岛素治疗DKA的T1D患者,这些患者在DKA发病后进行了血浆BOHB测量,并且DKA通过传统实验室标准(静脉pH值(vpH)≥7.3,血清碳酸氢盐(HCO3)≥15 mmol/L,和/或阴离子间隙(AG)≤14 mmol/L)得到解决。方法:通过散点图评估血浆BOHB与vpH、HCO3和AG之间的关系。采用受试者工作特征(ROC)曲线和曲线下面积(AUC)评价BOHB切点,预测DKA分辨率。结果:我们分析了403例患者的471例独特遭遇。血浆BOHB与AG的关系最为密切。血浆BOHB与公认的DKA分辨率定义(AG≤14 mmol/L)的ROC曲线比较,AUC为0.92。结论:血浆BOHB值为
{"title":"Utility of plasma beta-hydroxybutyrate to define resolution of diabetic ketoacidosis.","authors":"Elise Schlissel Tremblay, Kate Millington, Yunhong Wu, David Wypij, Yufan Yang, Michael S D Agus, Joseph Wolfsdorf","doi":"10.1111/pedi.13437","DOIUrl":"10.1111/pedi.13437","url":null,"abstract":"<p><strong>Background: </strong>Diabetic ketoacidosis (DKA) is a common, life-threatening complication of type 1 diabetes (T1D) characterized by unregulated ketogenesis caused by relative or absolute insulin deficiency. DKA management requires frequent biochemical monitoring. Plasma ß-hydroxybutyrate (BOHB) has not been included in traditional definitions of DKA resolution.</p><p><strong>Objective: </strong>The aim of this study was to determine a cut-point level of BOHB to define DKA resolution in patients with T1D treated with intravenous (IV) insulin.</p><p><strong>Subjects: </strong>We identified patients with T1D receiving IV insulin for DKA treatment at a quaternary children's hospital from January 1, 2017 through December 31, 2020 who had plasma measurements of BOHB after DKA onset and whose DKA resolved by traditional laboratory criteria (venous pH (vpH) ≥ 7.3, serum bicarbonate (HCO<sub>3</sub> ) ≥ 15 mmol/L, and/or anion gap (AG) ≤ 14 mmol/L).</p><p><strong>Methods: </strong>Associations between plasma BOHB and vpH, HCO<sub>3</sub> , and AG were evaluated via scatterplots. Receiver operating characteristic (ROC) curves and area under the curve (AUC) were used to evaluate BOHB cut-points to predict DKA resolution.</p><p><strong>Results: </strong>We analyzed 403 patients with 471 unique encounters. Plasma BOHB showed the most robust relationship with AG. The ROC curve comparing plasma BOHB to the accepted definition of DKA resolution, AG ≤14 mmol/L, had an AUC of 0.92. A BOHB value of <1.5 mmol/L had a sensitivity of 83% and specificity of 87%; this cut-point correctly classified 86% of the observations.</p><p><strong>Conclusions: </strong>A plasma BOHB value of <1.5 mmol/L can be used to define resolution of DKA.</p>","PeriodicalId":19797,"journal":{"name":"Pediatric Diabetes","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9772128/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10446943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
ISPAD Clinical Practice Consensus Guidelines 2022: Stages of type 1 diabetes in children and adolescents. ISPAD临床实践共识指南2022:儿童和青少年1型糖尿病的分期。
IF 3.4 3区 医学 Q1 Medicine Pub Date : 2022-12-01 DOI: 10.1111/pedi.13410
Rachel E J Besser, Kirstine J Bell, Jenny J Couper, Anette-G Ziegler, Diane K Wherrett, Mikael Knip, Cate Speake, Kristina Casteels, Kimberly A Driscoll, Laura Jacobsen, Maria E Craig, Michael J Haller
The stages of type 1 diabetes (T1D) provide common ground for global efforts to prevent DKA and delay progression to disease in children and adolescents: An ISPAD consensus guideline. with normal glucose tolerance (via OGTT); Stage 2=multiple AAb-positive with abnormal glucose tolerance; Stage 3=clinical diagnosis of T1D
{"title":"ISPAD Clinical Practice Consensus Guidelines 2022: Stages of type 1 diabetes in children and adolescents.","authors":"Rachel E J Besser,&nbsp;Kirstine J Bell,&nbsp;Jenny J Couper,&nbsp;Anette-G Ziegler,&nbsp;Diane K Wherrett,&nbsp;Mikael Knip,&nbsp;Cate Speake,&nbsp;Kristina Casteels,&nbsp;Kimberly A Driscoll,&nbsp;Laura Jacobsen,&nbsp;Maria E Craig,&nbsp;Michael J Haller","doi":"10.1111/pedi.13410","DOIUrl":"https://doi.org/10.1111/pedi.13410","url":null,"abstract":"The stages of type 1 diabetes (T1D) provide common ground for global efforts to prevent DKA and delay progression to disease in children and adolescents: An ISPAD consensus guideline. with normal glucose tolerance (via OGTT); Stage 2=multiple AAb-positive with abnormal glucose tolerance; Stage 3=clinical diagnosis of T1D","PeriodicalId":19797,"journal":{"name":"Pediatric Diabetes","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10499183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 40
Adolescent ambivalence about diabetes technology-The Janus faces of automated care. 青少年对糖尿病技术的矛盾心理——自动护理的两面脸。
IF 3.4 3区 医学 Q1 Medicine Pub Date : 2022-12-01 DOI: 10.1111/pedi.13423
Fergus J Cameron, Michael Arnold, John W Gregory

The Janus face metaphor approach highlights that a technology may simultaneously have two opposite faces or properties with unforeseen paradoxes within human-technology interaction. Suboptimal acceptance and clinical outcomes are sometimes seen in adolescents who use diabetes-related technologies. A traditional linear techno-determinist model of technology use would ascribe these unintended outcomes to suboptimal technology, suboptimal patient behavior, or suboptimal outcome measures. This paradigm has demonstratively not been successful at universally improving clinical outcomes over the last two decades. Alternatively, the Janus face metaphor moves away from a linear techno-determinist model and focuses on the dynamic interaction of the human condition and technology. Specifically, it can be used to understand variance in adoption or successful use of diabetes-related technology and to retrospectively understand suboptimal outcomes. The Janus face metaphor also allows for a prospective exploration of potential impacts of diabetes-related technology by patients, families, and their doctors so as to anticipate and minimize potential subsequent tensions.

双面神隐喻方法强调,一项技术可能同时具有两种相反的面孔或特性,在人机交互中具有不可预见的悖论。在使用糖尿病相关技术的青少年中,有时会出现不理想的接受度和临床结果。传统的线性技术决定模型将这些意外结果归因于次优技术、次优患者行为或次优结果测量。在过去的二十年中,这种模式在普遍改善临床结果方面并未取得成功。另一方面,双面神的隐喻脱离了线性的技术决定论模型,专注于人类条件和技术的动态相互作用。具体来说,它可以用来了解采用或成功使用糖尿病相关技术的差异,并回顾性地了解次优结果。两面脸的隐喻也允许对糖尿病相关技术的潜在影响进行前瞻性的探索,患者,家属和他们的医生,以预测和减少潜在的后续紧张。
{"title":"Adolescent ambivalence about diabetes technology-The Janus faces of automated care.","authors":"Fergus J Cameron,&nbsp;Michael Arnold,&nbsp;John W Gregory","doi":"10.1111/pedi.13423","DOIUrl":"https://doi.org/10.1111/pedi.13423","url":null,"abstract":"<p><p>The Janus face metaphor approach highlights that a technology may simultaneously have two opposite faces or properties with unforeseen paradoxes within human-technology interaction. Suboptimal acceptance and clinical outcomes are sometimes seen in adolescents who use diabetes-related technologies. A traditional linear techno-determinist model of technology use would ascribe these unintended outcomes to suboptimal technology, suboptimal patient behavior, or suboptimal outcome measures. This paradigm has demonstratively not been successful at universally improving clinical outcomes over the last two decades. Alternatively, the Janus face metaphor moves away from a linear techno-determinist model and focuses on the dynamic interaction of the human condition and technology. Specifically, it can be used to understand variance in adoption or successful use of diabetes-related technology and to retrospectively understand suboptimal outcomes. The Janus face metaphor also allows for a prospective exploration of potential impacts of diabetes-related technology by patients, families, and their doctors so as to anticipate and minimize potential subsequent tensions.</p>","PeriodicalId":19797,"journal":{"name":"Pediatric Diabetes","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a0/3d/PEDI-23-1717.PMC10091736.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9296997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Survival of children and youth with type 1 diabetes mellitus in Tanzania. 坦桑尼亚1型糖尿病儿童和青少年的生存率
IF 3.4 3区 医学 Q1 Medicine Pub Date : 2022-12-01 DOI: 10.1111/pedi.13425
Edna Siima Majaliwa, Linda Minja, Joel Ndayongeje, Kaushik Ramaiya, Sayoki G Mfinanga, Blandina T Mmbaga

Introduction: Survival from type 1 diabetes Mellitus is low in lower-income countries with underdeveloped health systems. Support programs from partners like life for a child (LFAC) and changing diabetes in children (CDiC) were implemented in Tanzania in 2005 to provide diabetes care to children and youth. No evaluation of survival has been done since their implementation.

Objective: To assess the survival of children and youth living with diabetes mellitus (CYLDM) in Tanzania.

Methods: A retrospective data collection from 39 clinics of CYLDM was done by extracting data from the diabetes registry between 1991 and 2019. Three cohort were analyzed (1) Cohort 1991-2004 (pre-implementation), (2) Cohort 2005-2010 (during implementation), and (3) 2011-2019 (after the implementation of LFAC/CDiC). Data were analyzed using STATA-version 14.

Results: A total of 3822 data of CYLDM were extracted, mean age at diagnosis was 13.8 (±5) years. Approximately fifty-one percent (50.8%) were male. The total observation time was 28 years, and the Median duration of diabetes of 5 (IQR2, 8) years. Total death was 95 (3%), with a mean age at death of 17.7 (SD 4.7) years. The last cohort (2011-2019) had more diagnosis 2353 (72.7%), as compared to the <2005 cohort with only 163(5%). The survival improved from 59% before 2005 to 69% in the last cohort (2011-2019).

Conclusion: The implemented programs have facilitated the diagnosis and retention of CYLDM in the health care system. In doing so, it has also increased the survival probability in Tanzania compared to the early 90s.

在卫生系统不发达的低收入国家,1型糖尿病患者的生存率较低。2005年,坦桑尼亚实施了“儿童生活”(LFAC)和“改变儿童糖尿病”(CDiC)等合作伙伴的支持项目,为儿童和青少年提供糖尿病护理。自实施以来,没有对生存情况进行评估。目的:评估坦桑尼亚儿童和青少年糖尿病患者(CYLDM)的生存率。方法:通过提取1991年至2019年糖尿病登记处的数据,回顾性收集39家CYLDM诊所的数据。分析了三个队列(1)1991-2004队列(实施前),(2)2005-2010队列(实施中)和(3)2011-2019队列(实施LFAC/CDiC后)。使用STATA-version 14分析数据。结果:共提取CYLDM资料3822例,平均诊断年龄为13.8(±5)岁。大约51%(50.8%)是男性。总观察时间28年,糖尿病中位病程5年(IQR2, 8)。总死亡95例(3%),平均死亡年龄17.7岁(SD 4.7)。最后一个队列(2011-2019)的诊断为2353例(72.7%),结论:实施的项目促进了CYLDM在医疗系统中的诊断和保留。在这样做的过程中,与90年代初相比,它也提高了坦桑尼亚的存活率。
{"title":"Survival of children and youth with type 1 diabetes mellitus in Tanzania.","authors":"Edna Siima Majaliwa,&nbsp;Linda Minja,&nbsp;Joel Ndayongeje,&nbsp;Kaushik Ramaiya,&nbsp;Sayoki G Mfinanga,&nbsp;Blandina T Mmbaga","doi":"10.1111/pedi.13425","DOIUrl":"https://doi.org/10.1111/pedi.13425","url":null,"abstract":"<p><strong>Introduction: </strong>Survival from type 1 diabetes Mellitus is low in lower-income countries with underdeveloped health systems. Support programs from partners like life for a child (LFAC) and changing diabetes in children (CDiC) were implemented in Tanzania in 2005 to provide diabetes care to children and youth. No evaluation of survival has been done since their implementation.</p><p><strong>Objective: </strong>To assess the survival of children and youth living with diabetes mellitus (CYLDM) in Tanzania.</p><p><strong>Methods: </strong>A retrospective data collection from 39 clinics of CYLDM was done by extracting data from the diabetes registry between 1991 and 2019. Three cohort were analyzed (1) Cohort 1991-2004 (pre-implementation), (2) Cohort 2005-2010 (during implementation), and (3) 2011-2019 (after the implementation of LFAC/CDiC). Data were analyzed using STATA-version 14.</p><p><strong>Results: </strong>A total of 3822 data of CYLDM were extracted, mean age at diagnosis was 13.8 (±5) years. Approximately fifty-one percent (50.8%) were male. The total observation time was 28 years, and the Median duration of diabetes of 5 (IQR2, 8) years. Total death was 95 (3%), with a mean age at death of 17.7 (SD 4.7) years. The last cohort (2011-2019) had more diagnosis 2353 (72.7%), as compared to the <2005 cohort with only 163(5%). The survival improved from 59% before 2005 to 69% in the last cohort (2011-2019).</p><p><strong>Conclusion: </strong>The implemented programs have facilitated the diagnosis and retention of CYLDM in the health care system. In doing so, it has also increased the survival probability in Tanzania compared to the early 90s.</p>","PeriodicalId":19797,"journal":{"name":"Pediatric Diabetes","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10431884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
ISPAD Clinical Practice Consensus Guidelines 2022: Nutritional management in children and adolescents with diabetes. ISPAD临床实践共识指南2022:糖尿病儿童和青少年的营养管理。
IF 3.4 3区 医学 Q1 Medicine Pub Date : 2022-12-01 DOI: 10.1111/pedi.13429
S Francesca Annan, Laurie A Higgins, Elisabeth Jelleryd, Tamara Hannon, Shelley Rose, Sheryl Salis, Juliana Baptista, Paula Chinchilla, Maria Loredana Marcovecchio
Paediatric Division, University College London Hospitals, London, UK Pediatric, Adolescent and Young Adult Section, Joslin Diabetes Center, Boston, Massachusetts, USA Medical Unit Clinical Nutrition, Karolinska University Hospital, Stockholm, Sweden School of Medicine, Indiana University, Indianapolis, Indiana, USA Diabetes & Endocrinology Service, MidCentral District Health Board, Palmerston North, New Zealand Department of Nutrition, Nurture Health Solutions, Mumbai, India Diabetes Training and Education, Medtronic, Sao Paulo, Brazil Women's and Children's Department, London North West Healthcare NHS Trust, London, UK Department of Paediatrics, University of Cambridge and Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
{"title":"ISPAD Clinical Practice Consensus Guidelines 2022: Nutritional management in children and adolescents with diabetes.","authors":"S Francesca Annan,&nbsp;Laurie A Higgins,&nbsp;Elisabeth Jelleryd,&nbsp;Tamara Hannon,&nbsp;Shelley Rose,&nbsp;Sheryl Salis,&nbsp;Juliana Baptista,&nbsp;Paula Chinchilla,&nbsp;Maria Loredana Marcovecchio","doi":"10.1111/pedi.13429","DOIUrl":"https://doi.org/10.1111/pedi.13429","url":null,"abstract":"Paediatric Division, University College London Hospitals, London, UK Pediatric, Adolescent and Young Adult Section, Joslin Diabetes Center, Boston, Massachusetts, USA Medical Unit Clinical Nutrition, Karolinska University Hospital, Stockholm, Sweden School of Medicine, Indiana University, Indianapolis, Indiana, USA Diabetes & Endocrinology Service, MidCentral District Health Board, Palmerston North, New Zealand Department of Nutrition, Nurture Health Solutions, Mumbai, India Diabetes Training and Education, Medtronic, Sao Paulo, Brazil Women's and Children's Department, London North West Healthcare NHS Trust, London, UK Department of Paediatrics, University of Cambridge and Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK","PeriodicalId":19797,"journal":{"name":"Pediatric Diabetes","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10441645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 20
ISPAD Clinical Practice Consensus Guidelines 2022: Insulin treatment in children and adolescents with diabetes. ISPAD临床实践共识指南2022:儿童和青少年糖尿病的胰岛素治疗。
IF 3.4 3区 医学 Q1 Medicine Pub Date : 2022-12-01 DOI: 10.1111/pedi.13442
Eda Cengiz, Thomas Danne, Tariq Ahmad, Ahila Ayyavoo, David Beran, Sarah Ehtisham, Jan Fairchild, Przemyslawa Jarosz-Chobot, Sze May Ng, Megan Paterson, Ethel Codner
University of California San Francisco (UCSF) Pediatric Diabetes Program, UCSF School of Medicine, San Francisco, California, USA Auf Der Bult, Diabetes Center for Children and Adolescents, Hannover, Germany Pediatric Endocrinology, UCSF Benioff Children's Hospital Oakland, Oakland, California, USA Department of Pediatrics, G. Kuppuswamy Naidu Memorial Hospital, Coimbatore, India Division of Tropical and Humanitarian Medicine, Faculty of Medicine University of Geneva and Geneva University Hospitals, Faculty of Medicine Diabetes Centre, Geneva, Switzerland Division of Pediatric Endocrinology, Mediclinic City Hospital, Dubai, UAE Department of Endocrinology and Diabetes, Women's and Children's Hospital, North Adelaide, Australia Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland Paediatric Department, Southport and Ormskirk NHS Trust, Southport, UK Department of Women's and Children's Health, University of Liverpool, Liverpool, UK John Hunter Children's Hospital, HRMC, New South Wales, Australia Institute of Maternal and Child Research (IDIMI), School of Medicine, University of Chile, Santiago, Chile
{"title":"ISPAD Clinical Practice Consensus Guidelines 2022: Insulin treatment in children and adolescents with diabetes.","authors":"Eda Cengiz,&nbsp;Thomas Danne,&nbsp;Tariq Ahmad,&nbsp;Ahila Ayyavoo,&nbsp;David Beran,&nbsp;Sarah Ehtisham,&nbsp;Jan Fairchild,&nbsp;Przemyslawa Jarosz-Chobot,&nbsp;Sze May Ng,&nbsp;Megan Paterson,&nbsp;Ethel Codner","doi":"10.1111/pedi.13442","DOIUrl":"https://doi.org/10.1111/pedi.13442","url":null,"abstract":"University of California San Francisco (UCSF) Pediatric Diabetes Program, UCSF School of Medicine, San Francisco, California, USA Auf Der Bult, Diabetes Center for Children and Adolescents, Hannover, Germany Pediatric Endocrinology, UCSF Benioff Children's Hospital Oakland, Oakland, California, USA Department of Pediatrics, G. Kuppuswamy Naidu Memorial Hospital, Coimbatore, India Division of Tropical and Humanitarian Medicine, Faculty of Medicine University of Geneva and Geneva University Hospitals, Faculty of Medicine Diabetes Centre, Geneva, Switzerland Division of Pediatric Endocrinology, Mediclinic City Hospital, Dubai, UAE Department of Endocrinology and Diabetes, Women's and Children's Hospital, North Adelaide, Australia Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland Paediatric Department, Southport and Ormskirk NHS Trust, Southport, UK Department of Women's and Children's Health, University of Liverpool, Liverpool, UK John Hunter Children's Hospital, HRMC, New South Wales, Australia Institute of Maternal and Child Research (IDIMI), School of Medicine, University of Chile, Santiago, Chile","PeriodicalId":19797,"journal":{"name":"Pediatric Diabetes","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10443764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 28
期刊
Pediatric Diabetes
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1